EnligHTN IV Trial - Multicenter Sham-controlled RCT of Renal Denervation for Hypertension

Hypertension Clinical Trial

— EnligHTN-IV  

Official title:

Multi-center, Randomized, Single-blind, Sham Controlled Clinical Investigation of Renal Denervation for Uncontrolled Hypertension

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01903187
• Other study ID #: 1204
• Status: Terminated
• Phase: N/A
• Start date: October 2013
• Est. completion date: November 2016

Study information

• Verified date: January 2019
• Source: Abbott Medical Devices
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the EnligHTN IV clinical investigation is to demonstrate the safety and effectiveness of the EnligHTN™ Renal Denervation System in the treatment of subjects with drug-resistant uncontrolled hypertension.

Description:

The study enrollment was terminated early by the sponsor. This was not related to any safety issue. At the time enrollment was halted, only 2 treatment group randomizations had occurred, and sham group subjects were exited after their 1 month follow up visit.

Subject randomized to the treatment group will be followed up for three years post procedure.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: November 2016
• Est. primary completion date: June 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Subject is =18 years of age and = 80 years of age at time of informed consent for participation in the clinical investigation

• Subject must be able and willing to provide written informed consent

• Subject must be able and willing to comply with the required follow-up schedule

• Subject has an office Systolic Blood Pressure = 160 mmHg based on an average of 3 Blood Pressure readings at the confirmatory visit (except for subjects with Diabetes Mellitus Type II who must demonstrate an office Systolic Blood Pressure of = 150 mmHg)

• Subject has a daytime mean Systolic 24-hour Ambulatory Blood Pressure value of = 140 mmHg as measured during the two week screening period and confirmed at the confirmatory visit

• Subject is taking = 3 antihypertensive medications concurrently at full tolerated doses (this must include one diuretic) or subject is taking a diuretic and has a documented intolerance to at least two (2) out of the three (3) remaining major classes of anti-hypertensives (ACE / ARB, Calcium Channel Blockers, Beta blockers and is unable to take 3 anti-hypertensive drugs)

o Intolerance is defined as an absolute contraindication to an anti-hypertensive medication according to the approved labeling or an inability to take an anti-hypertensive medication as prescribed due to an adverse drug effect including an immune mediated response or interaction with other medications.

• Subjects must be on a stable antihypertensive medication regimen for a minimum of 2 weeks prior to completing the initial screening visit and the medication regimen must remain unchanged during the 2 week screening period following signing consent. Subject must be assessed at the confirmatory visit with no expected changes for at least six (6) months

Exclusion Criteria:

• Subject has had a previous renal denervation attempt

• Subject has known cause of secondary hypertension other than sleep apnea

• Subjects with significant renovascular abnormalities such as renal artery stenosis >30%, previous renal stenting or angioplasty, renal artery occlusion, renal vein thrombosis, renal aneurysm or renal atheroembolism

• Subject has had a myocardial infarction, unstable angina pectoris, or cerebrovascular accident < 180 days prior to enrollment

• Subject has hemodynamically significant valvular heart disease as determined by a Study Investigator

• Subject is expected to have any cardiovascular intervention within 180 days of enrollment

• Subject has blood clotting abnormalities such as thrombocytopenia, hemophilia, or significant anemia

• Subject life expectancy is < 12 months, as determined by a Study Investigator

• Subject is participating in another Clinical Investigation (IND or IDE)

• Subject is pregnant, nursing, or of childbearing potential and is not using adequate contraceptive methods

• Subject has active systemic infection as determined by a Study Investigator

• Subject has main renal arteries with diameter(s) < 4 mm in diameter or < 20 mm in length or multiple renal arteries where the main renal arteries supply <75% of the kidney

• Subject has eGFR < 45 mL/min per 1.73 m2 using the MDRD formula

• Subject has evidence of significant AAA defined as an aneurysm size of =5.0 cm in width and/or involving the renal arteries, and/or requiring surgical or percutaneous intervention within 6 months of enrollment.

• Subject has had >1 in-patient hospitalization for a hypertensive crisis within 12 months

• Subject has a condition which would interfere with the accurate interpretation of the study endpoints

• Any condition that would prohibit or interfere with the ability to obtain accurate Blood Pressure measurements using the CIP specific automatic Blood Pressure monitor

• Subject has Systolic Blood Pressure values which are greater than 20mmHg apart after six (6) measurements as assessed at the confirmatory visit

Related Conditions & MeSH terms

• Hypertension

Intervention

Device:
• EnligHTN Renal Denervation
Renal artery angiogram plus bilateral renal denervation with the EnligHTN renal denervation system

Procedure:
• Sham
Renal artery angiogram

Locations

Country	Name	City	State
United States	Heart Center Research, LLC	Huntsville	Alabama
United States	Jackson Heart Clinic	Jackson	Mississippi
United States	Arkansas Heart Hospital	Little Rock	Arkansas

Sponsors (1)

Lead Sponsor	Collaborator
Abbott Medical Devices

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Primary Safety Endpoint Will be the Proportion of Subjects Who Experience Any Major Adverse Event (MAE) as Adjudicated by the Clinical Event Committee (CEC).	The study enrollment was terminated early by the sponsor. This was not related to any safety issue. At the time enrollment was halted, only 2 treatment group randomizations had occurred.	6 months post randomization
Primary	The Primary Effectiveness Endpoint is the Reduction of Office Systolic Blood Pressure (OSBP) at Six (6) Months Post Randomization Compared to Baseline Between Groups		6 months post randomization
Secondary	Device or Procedure Related Adverse Events by Severity Post Randomization Through Six (6) Months	The study enrollment was terminated early by the sponsor. This was not related to any safety issue. At the time enrollment was halted, only 2 treatment group randomizations had occurred, and sham group subjects were exited after their 1 month follow up visit. This was not enough to conduct the analysis.	6 months post randomization
Secondary	The Number of Subjects That Experience Each Type of MAE	The study enrollment was terminated early by the sponsor. This was not related to any safety issue. At the time enrollment was halted, only 2 treatment group randomizations had occurred, and sham group subjects were exited after their 1 month follow up visit. This was not enough to conduct the analysis.	6 months post randomization
Secondary	Incidence of Achieving = 10 mmHg, = 15 mmHg, and =20 mmHg Reductions in OSBP	The study enrollment was terminated early by the sponsor. This was not related to any safety issue. At the time enrollment was halted, only 2 treatment group randomizations had occurred, and sham group subjects were exited after their 1 month follow up visit. This was not enough to conduct the analysis.	6 months post randomization, and all follow-up timepoints
Secondary	Reduction in Ambulatory Blood Pressure (ABP) Parameters	The study enrollment was terminated early by the sponsor. This was not related to any safety issue. At the time enrollment was halted, only 2 treatment group randomizations had occurred, and sham group subjects were exited after their 1 month follow up visit. This was not enough to conduct the analysis.	baseline, 6 months post randomization, and all follow-up timepoints